דוסיטקסל טבע ® תמיסה מרוכזת בבקבוקון יחיד

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

DOCETAXEL 20 MG/ML

Available from:

ABIC MARKETING LTD

ATC code:

L01CD02

Pharmaceutical form:

CONCENTRATE FOR SOLUTION FOR INFUSION

Administration route:

I.V

Manufactured by:

PHARMACHEMIE B.V., THE NETHERLANDS

Therapeutic group:

DOCETAXEL

Therapeutic indications:

Breast cancer: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline

Authorization date:

2013-06-01